论文部分内容阅读
目的分析山莨菪碱雾化吸入治疗轻、中度支气管哮喘的临床疗效。方法选取2013年4月—2014年3月我院收治的轻、中度支气管哮喘患者143例,将其随机分为研究组86例和对照组57例。两组患者均进行常规治疗,对照组在常规治疗的基础上给予异丙托溴铵雾化吸入治疗,研究组在常规治疗的基础上给予山莨菪碱雾化吸入治疗,两组均治疗7 d。观察治疗前后肺功能〔用力肺活量(FVC)和最大呼气峰流速(PEF)〕变化、治疗后临床疗效及治疗期间不良反应情况。结果研究组总有效率为96.5%,高于对照组的87.7%(P<0.05)。治疗前两组患者FVC和PEF比较,差异均无统计学意义(P>0.05);治疗后研究组患者FVC和PEF高于对照组(P<0.05)。治疗期间两组患者均未发现明显不良反应。结论山莨菪碱雾化吸入治疗轻、中度支气管哮喘疗效显著,能有效改善肺功能且安全性高。
Objective To analyze the clinical effect of inhalation of anisodamine on mild and moderate bronchial asthma. Methods 143 patients with mild to moderate bronchial asthma admitted to our hospital from April 2013 to March 2014 were selected and randomly divided into study group (86 cases) and control group (57 cases). The two groups were treated routinely. The control group was given ipratropium bromide inhalation therapy on the basis of routine treatment. The study group was given inhalation of anisodamine on the basis of routine treatment. Both groups were treated for 7 days . The changes of pulmonary function (FVC) and maximum expiratory flow (PEF) before and after treatment were observed. The clinical effects and the adverse reactions during the treatment were observed. Results The total effective rate was 96.5% in the study group, which was 87.7% higher than that in the control group (P <0.05). There were no significant differences in FVC and PEF between the two groups before treatment (P> 0.05). After treatment, the FVC and PEF were higher in the study group than in the control group (P <0.05). During treatment, no significant adverse reactions were found in both groups. Conclusion Anisodamine inhalation treatment of mild and moderate bronchial asthma significant effect, can effectively improve lung function and high safety.